Forget the lazy days of summer–lab companies have been moving forward with deals. Here’s a look at key activity from mid-July through the third week of August.
Exact Sciences and Pfizer agreed to copromote Exact’s Cologuard colorectal cancer screening test Cologuard. Wall Street liked the news as shares of Exact soared on the announcement.
Meanwhile, 23andMe made a four-year deal making GlaxoSmithKline its sole drug discovery collaborator.
The period was also notable for new alliance activity in Asia, including:
- Oxford BioDynamics’ strategic alliance with GL Capital Group to help it establish a footprint in China;
- Genetic Technologies’ partnering with Zishan Health Consultancy to facilitate expansion into the Chinese market;
- Clearbridge Health Limited’s exclusive partnership with Hunan, China-based Agen Medicine Laboratory Technology Company.
- Qiagen’s non-exclusively collaboration with SRL, the largest clinical testing lab in Japan.
Here’s a summary of key diagnostic deals from mid-July through the third week in August:
